Maywufa Co Ltd

TW:1731 Taiwan Drug Manufacturers - Specialty & Generic
Market Cap
$87.58 Million
NT$2.90 Billion TWD
Market Cap Rank
#22130 Global
#1249 in Taiwan
Share Price
NT$21.80
Change (1 day)
-0.46%
52-Week Range
NT$20.20 - NT$24.20
All Time High
NT$27.70
About

Maywufa Company Ltd. manufactures and sells hair and skin care products under the Maywufa brand in Taiwan. The company engages in the manufacturing, processing, and distribution of hairdressing products, soap, and cosmetics; distribution, wholesale, and retail trading of various beauty products, health products, and sports equipment; retail and wholesale business of health food, such as vitamin p… Read more

Maywufa Co Ltd (1731) - Net Assets

Latest net assets as of September 2025: NT$2.08 Billion TWD

Based on the latest financial reports, Maywufa Co Ltd (1731) has net assets worth NT$2.08 Billion TWD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$3.11 Billion) and total liabilities (NT$1.02 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$2.08 Billion
% of Total Assets 67.09%
Annual Growth Rate 2.71%
5-Year Change 12.3%
10-Year Change 21.72%
Growth Volatility 5.65

Maywufa Co Ltd - Net Assets Trend (2002–2024)

This chart illustrates how Maywufa Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Maywufa Co Ltd (2002–2024)

The table below shows the annual net assets of Maywufa Co Ltd from 2002 to 2024.

Year Net Assets Change
2024-12-31 NT$2.11 Billion +3.42%
2023-12-31 NT$2.04 Billion +2.01%
2022-12-31 NT$2.00 Billion -0.44%
2021-12-31 NT$2.01 Billion +6.92%
2020-12-31 NT$1.88 Billion +6.75%
2019-12-31 NT$1.76 Billion +2.21%
2018-12-31 NT$1.72 Billion -2.13%
2017-12-31 NT$1.76 Billion +1.79%
2016-12-31 NT$1.73 Billion -0.28%
2015-12-31 NT$1.73 Billion +0.47%
2014-12-31 NT$1.72 Billion +2.20%
2013-12-31 NT$1.69 Billion +0.72%
2012-12-31 NT$1.67 Billion +1.44%
2011-12-31 NT$1.65 Billion -0.58%
2010-12-31 NT$1.66 Billion -0.42%
2009-12-31 NT$1.67 Billion +12.98%
2008-12-31 NT$1.47 Billion -2.24%
2007-12-31 NT$1.51 Billion +2.54%
2006-12-31 NT$1.47 Billion +4.70%
2005-12-31 NT$1.41 Billion -1.35%
2004-12-31 NT$1.42 Billion +23.35%
2003-12-31 NT$1.15 Billion -1.23%
2002-12-31 NT$1.17 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Maywufa Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 255.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings NT$343.38 Million 16.30%
Common Stock NT$1.33 Billion 63.09%
Other Comprehensive Income NT$243.21 Million 11.54%
Other Components NT$191.08 Million 9.07%
Total Equity NT$2.11 Billion 100.00%

Maywufa Co Ltd Competitors by Market Cap

The table below lists competitors of Maywufa Co Ltd ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Maywufa Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,037,156,000 to 2,106,819,000, a change of 69,663,000 (3.4%).
  • Net income of 173,232,000 contributed positively to equity growth.
  • Dividend payments of 152,853,000 reduced retained earnings.
  • Other comprehensive income increased equity by 27,993,000.
  • Other factors increased equity by 21,291,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income NT$173.23 Million +8.22%
Dividends Paid NT$152.85 Million -7.26%
Other Comprehensive Income NT$27.99 Million +1.33%
Other Changes NT$21.29 Million +1.01%
Total Change NT$- 3.42%

Book Value vs Market Value Analysis

This analysis compares Maywufa Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.38x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1.59x to 1.38x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2009-12-31 NT$13.74 NT$21.80 x
2010-12-31 NT$12.63 NT$21.80 x
2011-12-31 NT$12.54 NT$21.80 x
2012-12-31 NT$12.61 NT$21.80 x
2013-12-31 NT$12.67 NT$21.80 x
2014-12-31 NT$12.92 NT$21.80 x
2015-12-31 NT$13.00 NT$21.80 x
2016-12-31 NT$12.95 NT$21.80 x
2017-12-31 NT$13.19 NT$21.80 x
2018-12-31 NT$12.90 NT$21.80 x
2019-12-31 NT$13.19 NT$21.80 x
2020-12-31 NT$14.06 NT$21.80 x
2021-12-31 NT$15.05 NT$21.80 x
2022-12-31 NT$15.02 NT$21.80 x
2023-12-31 NT$15.29 NT$21.80 x
2024-12-31 NT$15.81 NT$21.80 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Maywufa Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 8.22%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 11.66%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 1.51x
  • Recent ROE (8.22%) is above the historical average (5.19%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 7.46% 2.74% 1.32x 2.06x NT$-29.72 Million
2003 5.75% 2.00% 1.36x 2.12x NT$-49.10 Million
2004 3.63% 1.32% 1.33x 2.07x NT$-90.69 Million
2005 2.15% 0.66% 1.56x 2.10x NT$-110.29 Million
2006 2.40% 0.71% 1.43x 2.37x NT$-108.60 Million
2007 4.16% 1.06% 1.81x 2.15x NT$-85.49 Million
2008 5.40% 2.52% 1.17x 1.83x NT$-65.65 Million
2009 3.56% 2.02% 1.01x 1.74x NT$-104.19 Million
2010 3.50% 1.93% 1.06x 1.71x NT$-107.84 Million
2011 2.55% 1.87% 0.91x 1.49x NT$-122.89 Million
2012 3.57% 2.78% 0.86x 1.49x NT$-107.64 Million
2013 3.77% 4.20% 0.59x 1.52x NT$-104.99 Million
2014 4.67% 6.53% 0.49x 1.46x NT$-91.75 Million
2015 4.57% 5.78% 0.52x 1.52x NT$-94.00 Million
2016 5.26% 6.29% 0.56x 1.51x NT$-81.86 Million
2017 4.89% 5.46% 0.59x 1.51x NT$-89.75 Million
2018 4.41% 6.74% 0.42x 1.55x NT$-96.18 Million
2019 5.72% 9.14% 0.40x 1.56x NT$-75.14 Million
2020 9.12% 16.05% 0.43x 1.32x NT$-16.60 Million
2021 8.19% 12.75% 0.48x 1.34x NT$-36.27 Million
2022 8.10% 13.00% 0.49x 1.27x NT$-37.87 Million
2023 8.30% 13.00% 0.46x 1.39x NT$-34.62 Million
2024 8.22% 11.66% 0.47x 1.51x NT$-37.45 Million

Industry Comparison

This section compares Maywufa Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,797,524,111
  • Average return on equity (ROE) among peers: 3.43%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Maywufa Co Ltd (1731) NT$2.08 Billion 7.46% 0.49x $41.33 Million
Grape King Bio Ltd (1707) $11.79 Billion 12.28% 0.30x $413.97 Million
Standard Chemical & Pharmaceutical Co Ltd (1720) $8.14 Billion 10.26% 0.37x $160.24 Million
Allied Biotech Corporation (1780) $1.17 Billion 8.33% 0.78x $47.92 Million
ScinoPharm Taiwan Ltd (1789) $9.38 Billion 5.16% 0.21x $180.77 Million
GeneFerm Biotechnology Co Ltd (1796) $396.19 Million 1.14% 1.48x $24.30 Million
Easywell Biomedicals Inc. (1799) $696.90 Million -39.00% 0.68x $62.14 Million
LIWANLI Innovation Co Ltd (3054) $799.59 Million 4.48% 0.55x $49.55 Million
YungShin Global Holding Corp (3705) $4.70 Billion 6.21% 0.18x $292.12 Million
TTY Biopharm Co Ltd (4105) $6.11 Billion 22.00% 0.56x $486.74 Million